» Articles » PMID: 16999828

Levels of Expression of Complement Regulatory Proteins CD46, CD55 and CD59 on Resting and Activated Human Peripheral Blood Leucocytes

Overview
Journal Immunology
Date 2006 Sep 27
PMID 16999828
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The cell surface complement regulatory (CReg) proteins CD46, CD55 and CD59 are widely expressed on human lymphoid and non-lymphoid cells. This study aimed to compare systematically levels of CReg expression by different leucocyte subsets and to determine whether levels were increased following activation in vitro. Levels of each CReg protein were similar on freshly isolated monocytes and all major lymphocyte subsets, except that CD4(+) cells expressed significantly less CD46 than CD8(+) cells (P < 0.05) while the reverse was observed for CD55 (P < 0.02). CD56(+) cells, predominantly natural killer cells, expressed significantly lower levels of CD59 than T cells (P < 0.02). CD45RO(+) cells had higher levels of surface CD46 and CD59, but lower levels of CD55, than CD45RO(-) cells (P < 0.02); CD25(+) cells also expressed significantly less CD55 than CD25(-) cells (P < 0.002). Neutrophils expressed higher levels of CD59, but lower levels of CD55, than monocytes. Following activation with phytohaemagglutinin, CD46 was up-regulated on all leucocyte subsets with the exception of CD56(+) cells. Both CD55 and CD59 were also markedly up-regulated on monocytes, and CD55 expression was greater on CD8(+) than CD4(+) cells following activation (P < 0.02). Lipopolysaccharide treatment did not significantly alter B-cell expression of CReg proteins whereas CD55 and CD59, but not CD46, were significantly up-regulated on monocytes (P < 0.02). These observations that CReg proteins are up-regulated on certain activated leucocyte subsets indicate that levels would be increased following immune responses in vivo. This could enhance both protection against local complement activation at inflammatory sites and also the immunoregulatory properties of these leucocytes.

Citing Articles

The role of complement in tumor immune tolerance and drug resistance: a double-edged sword.

Yang R, Fu D, Liao A Front Immunol. 2025; 16:1529184.

PMID: 39958348 PMC: 11825488. DOI: 10.3389/fimmu.2025.1529184.


Respiratory extracellular vesicle isolation optimization through proteomic profiling of equine samples and identification of candidates for cell-of-origin studies.

Hickman E, Carberry V, Carberry C, Cooper B, Mordant A, Mills A PLoS One. 2025; 20(1):e0315743.

PMID: 39854355 PMC: 11760557. DOI: 10.1371/journal.pone.0315743.


Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions.

McKeague M, Lohmueller J, Dracz M, Saadallah N, Ricci E, Beckwith D Antibodies (Basel). 2024; 13(4.

PMID: 39449327 PMC: 11503386. DOI: 10.3390/antib13040085.


Erythropoietin Effect on Complement Activation in Chronic Kidney Disease.

Athanasiadou V, Ampelakiotou K, Grigoriou E, Psarra K, Tsirogianni A, Valsami S Biomedicines. 2024; 12(8).

PMID: 39200211 PMC: 11351309. DOI: 10.3390/biomedicines12081746.


Association of Blood Group Antigen CD59 with Disease.

Weinstock C Transfus Med Hemother. 2022; 49(1):13-24.

PMID: 35221864 PMC: 8832213. DOI: 10.1159/000521174.


References
1.
MacPherson G, Pugh C . Heterogeneity amongst lymph-borne "dendritic" cells. Immunobiology. 1984; 168(3-5):338-48. DOI: 10.1016/S0171-2985(84)80121-7. View

2.
Smith L . Paroxysmal nocturnal hemoglobinuria. Clin Lab Sci. 2004; 17(3):172-7. View

3.
Valitutti S, Carbone A, Castellino F, Maggiano N, Ricci R, Larocca L . The expression of functional IL-2 receptor on activated macrophages depends on the stimulus applied. Immunology. 1989; 67(1):44-50. PMC: 1385286. View

4.
Tausk F, Fey M, Gigli I . Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells. J Immunol. 1989; 143(10):3295-302. View

5.
Ohashi Y, Takeshita T, Nagata K, Mori S, Sugamura K . Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells. J Immunol. 1989; 143(11):3548-55. View